Back to top

Analyst Blog

BioSpecifics Technologies recently announced positive top line data from a phase IIa study on Xiaflex for the potential treatment of frozen shoulder syndrome (FSS) in adults. BioSpecifics has a strategic partnership with Auxilium Pharmaceuticals, Inc. (AUXL - Analyst Report) for Xiaflex.

The open-label controlled dose-ranging phase IIa study, conducted by Auxilium Pharma, evaluated the safety and efficacy of Xiaflex for the treatment of stage II unilateral idiopathic frozen shoulder in comparison with an exercise-only group.

The study involved 50 adults, equally divided into 5 groups. Four such cohorts received up to three injections of Xiaflex (doses ranging from 0.29 mg to 0.58mg in three different volumes: 0.5, 1.0, or 2.0 mL) in addition to home shoulder exercises. The fifth cohort only performed home shoulder exercises.

Dosing arms – 0.58mg (1mL) and 0.58mg (2mL) – showed statistically significant positive improvement from baseline in forward flexion versus the exercise-only group.
 
We note that Xiaflex, an injectable enzyme, is already available for the treatment of Dupuytren’s contracture (DC). DC refers to a condition that affects the connective tissue in the palm known as palmar fascia. BioSpecifics Technologies /Auxillium Pharma are evaluating the drug for other indications also. Xiaflex is currently under FDA review for the Peyronie’s indication (PD). A response from the agency should be out by Sep 6, 2013.

Both BioSpecifics and Auxilium Pharma carry a Zacks Rank #3 (Hold). Currently, companies like Lannett Company, Inc. (LCI ) and WuXi Pharma Tech (Cayman) Inc. (WX - Snapshot Report) look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
PANTRY INC PTRY 21.02 +2.09%
INTEL CORP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%